Response to "Comment on sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma".
Journal
Journal of the Formosan Medical Association
ISSN
0929-6646
Date Issued
2025-02-10
Author(s)
Luo, Pei-Jui
DOI
10.1016/j.jfma.2025.02.004
Publisher
Elsevier B.V.
Type
letter